Japan Chronic Pain Market Size, Share, and COVID-19 Impact Analysis, By Indication (Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, and Migraine), By Drug Class (Opioids, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Anticonvulsants, Antidepressants, and Others), and Japan Chronic Pain Market Insights, Industry Trend, Forecasts to 2035

Japan Chronic Pain Market Size Insights Forecasts to 2035

• The Japan Chronic Pain Market Size Was Estimated at USD 3,981.17 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.08% from 2025 to 2035
• The Japan Chronic Pain Market Size is Expected to Reach USD 7,619.21 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the Japan Chronic Pain Market Size is anticipated to reach USD 7,619.21 Million by 2035, growing at a CAGR of 6.08% from 2025 to 2035. The market is propelled by Japan’s ageing population and increasing prevalence of chronic pain disorders, coupled with technological advances in pain management options like minimally invasive procedures and digital health tools.

Market Overview

The Japan chronic pain market encompasses healthcare products and interventions aimed at managing long-term pain conditions, such as neuropathy, arthritis, and lower back pain, including both pharmacological treatments and non-drug modalities. In Japan, a large percentage of people suffer from chronic pain, which is a common health problem. Japan's aging population is contributing to an increase in the prevalence of age-related chronic illnesses such as back pain and arthritis. The nation has one of the largest percentages of older people in the world, and chronic pain is becoming more and more common there. Additionally, the issue is made worse by lifestyle variables, including bad eating habits and sedentary behavior, which raises the need for efficient pain management options.

Report Coverage

This research report categorizes the market for the Japan chronic pain market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan chronic pain market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan chronic pain market.

Driving Factors

The rising incidence of chronic diseases like arthritis, neuropathy, and lower back pain, as well as an aging population that is more vulnerable to these problems, are the main factors propelling the chronic pain market in Japan. The market is expanding as a result of growing knowledge of pain management choices and improvements in therapeutic options, such as non-invasive procedures and novel drug formulations. Government programs to promote access to pain management treatments and healthcare infrastructure also play a big role in the market's growth. New developments are becoming more popular, like the use of digital health tools for pain management and individualized treatment plans. Concerns about opioid dependence have led to an increased emphasis on non-opioid pain management options, which has a beneficial impact on the market.

Restraining Factors

The market is hampered by a number of factors, including insufficient reimbursement coverage for newer pain treatments, a lack of specialized pain management clinics and qualified professionals, high treatment costs, particularly for novel therapies, which can limit patient access; Japan's strict regulatory environment, which frequently delays approval and market entry; and a persistent focus on traditional therapies and lifestyle changes, which can reduce uptake of advanced options.

Market Segmentation

The Japan chronic pain market share is classified into indication and drug class.

• The neuropathic pain segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan chronic pain market is segmented by indication into neuropathic pain, arthritis pain, chronic back pain, cancer pain, and migraine. Among these, the neuropathic pain segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the increasing incidence of diabetes and other nerve-related disorders among Japan's aging population, and neuropathic pain accounts for a sizeable portion of the market.

• The non-steroidal anti-inflammatory drugs (NSAIDs) segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan chronic pain market is segmented by drug class into opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and others. Among these, the non-steroidal anti-inflammatory drugs (NSAIDs) segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because of their widespread availability and effectiveness; NSAIDs are the market leader and provide first-line treatment for a variety of chronic pain problems.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan chronic pain market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott Laboratories
• Pfizer Inc.
• Eli Lilly & Company
• Cara Therapeutics
• Chattem (Sanofi)
• Endo International plc
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan Chronic Pain Market based on the below-mentioned segments:

Japan Chronic Pain Market, By Indication

• Neuropathic Pain
• Arthritis Pain
• Chronic Back Pain
• Cancer Pain
• Migraine

Japan Chronic Pain Market, By Drug Class

• Opioids
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Anticonvulsants
• Antidepressants
• Others